Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24735238 | 0.93 | CYP2D6 (0.30) | CYP2D6 | |
| SCHEMBL20375692 | 0.90 | CYP2D6 (0.36) | CYP2D6HRH3 | |
| SCHEMBL26328605 | 0.87 | CYP2D6 (0.34) | CYP2D6HRH3 | |
| SCHEMBL22918414 | 0.87 | CYP2D6 (0.34) | CYP2D6HRH3 | |
| SCHEMBL22645245 | 0.86 | CYP2D6 (0.36) | CYP2D6HRH3 | |
| SCHEMBL24941850 | 0.81 | CYP2D6 (0.35) | CYP2D6HRH3 | |
| SCHEMBL19083175 | 0.81 | CYP2D6 (0.32) | CYP2D6 | |
| SCHEMBL23551954 | 0.80 | HRH3 (0.33) | HRH3 | |
| SCHEMBL10111446 | 0.80 | CYP2D6 (0.42) | CYP2D6KDM4EMEN1KMT2AHRH3 | |
| SCHEMBL10111455 | 0.80 | CYP2D6 (0.38) | CYP2D6HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10973810-B2 | Methods for the treatment of neurological disorders | YUMANITY THERAPEUTICS, INC. (US) | 2021-04-13 | — | — | US | disclosed |
| US-20180193325-A1 | METHODS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | JANSSEN PHARMACEUTICA NV (BE) | 2018-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10973810-B2 | Methods for the treatment of neurological disorders | NLN, CLN6, OTC | CYP2D6 1415/4885KDM4E 3693/4885MEN1 2780/4885 |
| US-20180193325-A1 | METHODS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | NLN, CLN6, OTC | CYP2D6 1415/4885KDM4E 3693/4885MEN1 2780/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.